They joined us !
Creation : August, 20th 2023
Employees : 2
Turnover : 0 (N/A)
Place : Lyon, France
Activity (biotech/medtech/healthtech) : biotech
Who ?
Kanēov SAS specializes in the development and production of preclinical and clinical batches of Active Pharmaceutical Ingredients (APIs) derived from Cannabis.
In response to recent legislative developments in France, which now authorize the medical use of cannabis under prescription in specific indications following a successful trial, our company offers an integrated solution for:
Our mission is to support scientific and medical advancements by providing high-quality products for the development of Cannabis-based treatments while conducting our own clinical studies on targeted indications. »
Why ?
« Medical cannabis will be legalized in France in 2025, opening a rare opportunity to enter this market, which will allow patients to find relief in five therapeutic indications from the outset.
By joining Lyonbiopole, kanēov is embracing innovation with the goal of enabling medical cannabis to address additional indications. Indeed, Lyonbiopoe offers an environment conducive to innovation, notably through collaborations and partnerships facilitated by the cluster. This will allow kanēov to accelerate its development by accessing additional funding sources and participating in cutting-edge training in the health sector. Moreover, it presents an opportunity to expand internationally in the long term by leveraging the cluster’s global network.
By integrating into Lyonbiopole, kanēov strengthens its position to become a key player in medical cannabis in France, focusing on innovation and strategic partnerships to improve the range of care offered to patients. »
Julien THERIER
President-Foudner